Fate Therapeutics Inc. (FATE)
NASDAQ
Closed
Oct 23, 2026
Day's Range
2.0252 wk Range
0.9500Overview - FATE - Fate Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
183.11M
P/E (Trailing)
-1.85
P/E (Forward)
-2.25
PEG Ratio
0.13
Price / Sales (TTM)
40.24
Price / Book
1.65
EV / EBITDA
-1.52
Profitability
Profit Margin
0.00%
Operating Margin
-1,495.38%
Return on Assets
-26.21%
Return on Equity
-60.75%
Ownership
Shares Outstanding
116.69M
Float
105.48M
Short % of Shares Outstanding
10.14%
Held by Insiders
1.06%
Held by Institutions
69.03%
Price stats
Beta
2.52
50-Day Avg
2.46
200-Day Avg
1.88
Analyst Consensus
11 analysts
Average price target
$ 5.74Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - FATE - Fate Therapeutics Inc.
Peers - FATE - Fate Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- FATENASDAQFate Therapeutics Inc.255.21MMarket Cap+29.58%52-week change-1.86P/E (Trailing)0.00%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - FATE - Fate Therapeutics Inc.
About
Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases. The company uses its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cell therapy candidates, including natural killer…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
